Close menu




October 9th, 2025 | 07:10 CEST

Dividends and growth? It is possible! With RE Royalties, Royalty Pharma or Evonik

  • financing
  • royalties
  • renewableenergies
  • Pharma
  • chemicals
Photo credits: pixabay.com

The stock market is not just about price increases; dividends are also highly attractive. There are even professional investor groups that focus almost exclusively on continuous returns. Examples include pension funds and insurers. But why do companies in some sectors distribute more profits than others? We take a closer look at three exciting stocks that are also income generators and explain which business models offer the greatest potential from an investor's perspective.

time to read: 3 minutes | Author: Nico Popp
ISIN: RE ROYALTIES LTD | CA75527Q1081 , ROYALTY PHARMA OA DL-0001 | GB00BMVP7Y09 , EVONIK INDUSTRIES NA O.N. | DE000EVNK013

Table of contents:


    Evonik scores with its business model and dividends

    When German investors seek stable returns from domestic companies, they often turn to Evonik shares. The specialty chemicals group offers a wide range of chemical products and is therefore considered stable within what is actually a cyclical industry. Evonik pursues a consistent dividend policy and has never reduced its dividend payout since going public more than ten years ago. Today, Evonik shares offer a stable dividend yield of around 8% – placing the Company at the top of the MDAX dividend ranking. The combination of a stable business model and a consistent dividend policy appeals to many investors. Analysts are also relatively optimistic about Evonik.

    Royalties almost mask the economic cycle – More and more exciting niches

    Business models that rely on so-called royalties promise even more stable earnings. Royalties are steady income streams in the form of usage or license fees, as is common in mining or the pharmaceutical industry, for example. Founded in 2000, Royalty Pharma is now the world's largest buyer of drug royalties. The business model: Royalty Pharma provides capital to biotech companies and pharmaceutical developers – for example, for research financing or acquisitions – and in return receives contractually secured revenue shares from approved drugs. These royalty streams bring capital into the coffers completely independently of the economic situation. The large number of royalties also ensures a diversified cash flow pool. Royalty Pharma's stock fluctuates significantly less than others; the Company consistently buys back its own shares and also offers a quarterly dividend. In the rather hectic biotech business, the Company occupies an interesting niche.

    RE Royalties finances clean energy – and scores with a 9% dividend

    The Canadian company RE Royalties is also unique in its approach. The specialists in financing sustainable energy projects raise capital through bonds and invest it in selected projects in the fields of solar, wind power, hydropower, and battery storage. In return, the operators guarantee RE Royalties regular payments. RE Royalties currently offers a diversified portfolio with over 100 projects from more than ten jurisdictions and various technologies. This generates robust cash flows that ensure the Company can guarantee a stable dividend. Since 2020, RE Royalties has been paying a quarterly dividend of CAD 0.01 – based on the current share price and annualized, this results in an extremely attractive dividend yield of around 9%.

    For bond investors, RE Royalties also offers green bonds: The Company has already issued several green bonds to finance new projects. At the end of 2024, it raised around CAD 6.2 million, paying investors a coupon of 9% per annum until maturity in 2029. The bonds are secured by the royalty and loan portfolio and are earmarked for verifiably sustainable investments in accordance with the ICMA Green Bond Principles. As S&P Global has positively reviewed the green bond framework, interested investors can also take a look at these bonds. A combination of shares and bonds can also be attractive depending on market conditions - despite RE Royalties' long-standing track record, the Company, with its innovative business model, is still not widely known among investors. Valuation anomalies that savvy investors can exploit are therefore quite possible.

    Stability anchor for your portfolio: RE Royalties shares and green bonds

    While royalty companies have long been present in the energy and mining sectors, RE Royalties occupies an interesting niche with its royalties from renewable energy plants. This means that the Company faces little direct competition when issuing bonds and can offer attractive terms. The possibility of debt financing also prevents shareholder dilution, making the stock even more appealing. Even though RE Royalties' stock has lost 6.5% over the past six months, this has been more than offset by its stable dividend. The growth outlook is also promising: according to the International Energy Agency (IEA), around USD 2.2 trillion will be invested in clean energy technologies in 2025, which is twice as much as in fossil fuels for the first time.


    With its expertise in renewable projects and the associated financing, RE Royalties offers an exciting investment story for all investors looking to add a stable and sustainable position with the prospect of further returns to their portfolio. The bonds are also worth considering for investors familiar with the asset class or for professional investors.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Carsten Mainitz on October 12th, 2026 | 05:28 CEST

    Don’t Miss Out! Cancer Research and Comeback Potential: Vidac Pharma, Bayer and Evotec in Focus!

    • Oncology
    • Cancer Therapy
    • Pharma
    • Biotechnology
    • Clinical Trials
    • Innovation

    New cancer therapies are targeting major medical breakthroughs. For investors, however, the key question is when scientific progress will begin to translate into rising share prices. Vidac Pharma is at a particularly exciting stage in its development. The company is awaiting crucial clinical trial data that could validate its innovative approach to cancer cell metabolism and mark a major milestone. Bayer is expanding its oncology business but must also contend with a range of challenges. Meanwhile, Evotec needs to prove it can turn its research, technology platforms, and strategic partnerships into profitable business opportunities while rebuilding lost investor confidence. Which developments could now trigger a revaluation of these three stocks?

    Read

    Commented by André Will-Laudien on October 9th, 2026 | 10:59 CEST

    BioTech Rally 2027: Patents, Blockbusters and Biosimilars! The spotlight is on Bayer, Formycon, Evotec and Novo Nordisk

    • Biotechnology
    • Biotech
    • Pharma
    • biosimilars
    • patents

    The storm in the pharmaceutical sector continues to gain momentum! Expiring patents and struggling healthcare systems are shaking up old, high-margin blockbuster drugs, as societal changes and government budget constraints shake the foundations of costly pharmaceutical development. As patents expire, many generic manufacturers find themselves in a race against time. Market shares are being reshuffled, heralding a new era of growth. Amid this dynamic rally, four well-known industry players are positioning themselves on different fronts to capitalize on the market shifts. After several difficult years, the Leverkusen-based pharmaceutical giant Bayer is fighting its way back with a completely revamped pipeline. Also in the fast lane is the German biosimilar hopeful from Munich, with its first products already on the market. At Hamburg-based drug discovery company Evotec, restructuring is still underway; the key driver is its state-of-the-art, AI-powered multivalent platform. Meanwhile, the Danish giant Novo Nordisk continues to ride the global obesity and diabetes wave, driving forward the next generation of its blockbuster drugs. Analysts do not have it easy, but there are plenty of opportunities for investors.

    Read